Literature DB >> 24089925

Molecular radiotherapy: the NUKFIT software for calculating the time-integrated activity coefficient.

P Kletting1, S Schimmel, H A Kestler, H Hänscheid, M Luster, M Fernández, J H Bröer, D Nosske, M Lassmann, G Glatting.   

Abstract

PURPOSE: Calculation of the time-integrated activity coefficient (residence time) is a crucial step in dosimetry for molecular radiotherapy. However, available software is deficient in that it is either not tailored for the use in molecular radiotherapy and/or does not include all required estimation methods. The aim of this work was therefore the development and programming of an algorithm which allows for an objective and reproducible determination of the time-integrated activity coefficient and its standard error.
METHODS: The algorithm includes the selection of a set of fitting functions from predefined sums of exponentials and the choice of an error model for the used data. To estimate the values of the adjustable parameters an objective function, depending on the data, the parameters of the error model, the fitting function and (if required and available) Bayesian information, is minimized. To increase reproducibility and user-friendliness the starting values are automatically determined using a combination of curve stripping and random search. Visual inspection, the coefficient of determination, the standard error of the fitted parameters, and the correlation matrix are provided to evaluate the quality of the fit. The functions which are most supported by the data are determined using the corrected Akaike information criterion. The time-integrated activity coefficient is estimated by analytically integrating the fitted functions. Its standard error is determined assuming Gaussian error propagation. The software was implemented using MATLAB.
RESULTS: To validate the proper implementation of the objective function and the fit functions, the results of NUKFIT and SAAM numerical, a commercially available software tool, were compared. The automatic search for starting values was successfully tested for reproducibility. The quality criteria applied in conjunction with the Akaike information criterion allowed the selection of suitable functions. Function fit parameters and their standard error estimated by using SAAM numerical and NUKFIT showed differences of <1%. The differences for the time-integrated activity coefficients were also <1% (standard error between 0.4% and 3%). In general, the application of the software is user-friendly and the results are mathematically correct and reproducible. An application of NUKFIT is presented for three different clinical examples.
CONCLUSIONS: The software tool with its underlying methodology can be employed to objectively and reproducibly estimate the time integrated activity coefficient and its standard error for most time activity data in molecular radiotherapy.

Mesh:

Year:  2013        PMID: 24089925     DOI: 10.1118/1.4820367

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  18 in total

1.  Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand.

Authors:  Stefano Boschi; Jason T Lee; Seval Beykan; Roger Slavik; Liu Wei; Claudio Spick; Uta Eberlein; Andreas K Buck; Filippo Lodi; Gianfranco Cicoria; Johannes Czernin; Michael Lassmann; Stefano Fanti; Ken Herrmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-22       Impact factor: 9.236

2.  The Influence of Early Measurements Onto the Estimated Kidney Dose in [(177)Lu][DOTA(0),Tyr(3)]Octreotate Peptide Receptor Radiotherapy of Neuroendocrine Tumors.

Authors:  Andreas Delker; Harun Ilhan; Christian Zach; Julia Brosch; Franz Josef Gildehaus; Sebastian Lehner; Peter Bartenstein; Guido Böning
Journal:  Mol Imaging Biol       Date:  2015-10       Impact factor: 3.488

3.  Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy.

Authors:  Ken Herrmann; Christina Bluemel; Martina Weineisen; Margret Schottelius; Hans-Jürgen Wester; Johannes Czernin; Uta Eberlein; Seval Beykan; Constantin Lapa; Hubertus Riedmiller; Markus Krebs; Saskia Kropf; Andreas Schirbel; Andreas K Buck; Michael Lassmann
Journal:  J Nucl Med       Date:  2015-04-16       Impact factor: 10.057

4.  A review of 3D image-based dosimetry, technical considerations and emerging perspectives in 90Y microsphere therapy.

Authors:  Jim O' Doherty
Journal:  J Diagn Imaging Ther       Date:  2015-04-28

5.  (177)Lu-OPS201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model.

Authors:  Seval Beykan; Jan S Dam; Uta Eberlein; Jens Kaufmann; Benedict Kjærgaard; Lars Jødal; Hakim Bouterfa; Romain Bejot; Michael Lassmann; Svend Borup Jensen
Journal:  EJNMMI Res       Date:  2016-06-13       Impact factor: 3.138

6.  Microscale radiosynthesis, preclinical imaging and dosimetry study of [18F]AMBF3-TATE: A potential PET tracer for clinical imaging of somatostatin receptors.

Authors:  Ksenia Lisova; Maxim Sergeev; Susan Evans-Axelsson; Andreea D Stuparu; Seval Beykan; Jeffrey Collins; Jason Jones; Michael Lassmann; Ken Herrmann; David Perrin; Jason T Lee; Roger Slavik; R Michael van Dam
Journal:  Nucl Med Biol       Date:  2018-04-20       Impact factor: 2.408

7.  Personalized dosimetry for a deeper understanding of metastatic response to high activity 131I-mIBG therapy in high risk relapsed refractory neuroblastoma.

Authors:  Bartolomeo Cassano; Milena Pizzoferro; Silvio Valeri; Claudia Polito; Salvatore Donatiello; Claudio Altini; Maria Felicia Villani; Annalisa Serra; Aurora Castellano; Maria Carmen Garganese; Vittorio Cannatà
Journal:  Quant Imaging Med Surg       Date:  2022-02

8.  Physiologically Based Pharmacokinetic Modeling Is Essential in 90Y-Labeled Anti-CD66 Radioimmunotherapy.

Authors:  Peter Kletting; Christian Maaß; Sven Reske; Ambros J Beer; Gerhard Glatting
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

9.  Investigating the Effect of Ligand Amount and Injected Therapeutic Activity: A Simulation Study for 177Lu-Labeled PSMA-Targeting Peptides.

Authors:  Peter Kletting; Christiane Schuchardt; Harshad R Kulkarni; Mostafa Shahinfar; Aviral Singh; Gerhard Glatting; Richard P Baum; Ambros J Beer
Journal:  PLoS One       Date:  2016-09-09       Impact factor: 3.240

10.  Novel Approach to Repeated Arterial Blood Sampling in Small Animal PET: Application in a Test-Retest Study with the Adenosine A1 Receptor Ligand [(11)C]MPDX.

Authors:  Jürgen W A Sijbesma; Xiaoyun Zhou; David Vállez García; Martin C Houwertjes; Janine Doorduin; Chantal Kwizera; Bram Maas; Peter Meerlo; Rudi A Dierckx; Riemer H J A Slart; Philip H Elsinga; Aren van Waarde
Journal:  Mol Imaging Biol       Date:  2016-10       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.